Jan. 12 at 2:28 PM
$ALUR
Fourth quarter revenue of
$3.3 million to
$3.7 million, a 22% to 37% increase quarter-over-quarter, and full-year revenue of approximately
$15 million
Substantial improvement in operating expenses and operating loss quarter-over-quarter and as compared to prior year
“We are pleased with our results from the fourth quarter, where we grew revenue meaningfully quarter-over-quarter for the first time in more than one year as our new commercial strategy implemented after our strategic pivot in 2025 began to take hold,” said Dr. Shantanu Gaur, Founder and Chief Executive Officer. “We have also continued to reduce our operating losses through a sharpening of our strategic focus, and, with that, I believe we have set ourselves up for an even more efficient 2026. With a potential FDA approval of our Allurion Smart Capsule on the horizon, I believe 2026 will be a historic year for Allurion.”
$ALLO $ZNTL $NVO $VKTX
